Brokers Offer Predictions for CNTX Q3 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2025 earnings at ($0.05) EPS.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01.

Other equities analysts also recently issued research reports about the company. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. JMP Securities started coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective on the stock. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Friday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $6.17.

Context Therapeutics Trading Down 1.0 %

NASDAQ:CNTX opened at $0.76 on Monday. The business’s fifty day moving average price is $0.85 and its 200 day moving average price is $1.42. The firm has a market capitalization of $57.30 million, a price-to-earnings ratio of -0.84 and a beta of 2.06. Context Therapeutics has a 1-year low of $0.64 and a 1-year high of $2.75.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Context Therapeutics during the 4th quarter worth $29,000. Citadel Advisors LLC bought a new stake in Context Therapeutics in the fourth quarter worth $31,000. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics during the third quarter worth $89,000. Shay Capital LLC bought a new position in Context Therapeutics during the fourth quarter valued at about $52,000. Finally, Clear Harbor Asset Management LLC lifted its position in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.